Two of the Company's drug candidates are in Phase II clinical trials. The Company's drug candidates target major cardiovascular diseases such as heart attack, unstable angina, deep vein thrombosis and pulmonary embolism, as well as cancer and acute inflammation associated with reperfusion injury in ischemic stroke.
Results reflect a decrease in revenue recognized from collaborative agreements.
Lower loss reflects cash received from the November 2000 public offering. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Event data provided by StreetEvents .